Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Targovax ASA ( (GB:0RIS) ) has issued an announcement.
Circio Holding ASA held its annual general meeting, where all board proposals, including the approval of the 2024 annual accounts, were accepted. This meeting underscores Circio’s commitment to advancing its innovative RNA technologies and cancer vaccine development, potentially strengthening its position in the biotechnology industry and offering significant implications for stakeholders through its ongoing research and collaborations.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced RNA technology for nucleic acid medicine. The company has created a unique circular RNA vector expression platform, known as circVec, which enhances protein expression significantly compared to traditional mRNA systems. This platform is applicable in various therapeutic areas, including genetic medicine and chronic diseases. Circio is also working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,297,418
Current Market Cap: NOK66.7M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue